Interferon-associated thyroid dysfunction in anti-D-related chronic hepatitis C

Journal of Interferon and Cytokine Research

Volumn 17, Issue 7, 1997, Pages 409-411

  Sachithanandan, S ^a   Clarke, G ^b   Crowe, J ^b   Fielding, J F ^a,b  

^a BEAUMONT HOSPITAL   (Ireland)

^b MATER PRIVATE HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBIMAZOLE; RIBAVIRIN; THYROXINE;

ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DOSE RESPONSE; HEPATITIS C; HORMONE SUBSTITUTION; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; THYROIDITIS; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 0030813498     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1997.17.409     Document Type: Article

References (17)

1. ESTEBAN, J.R., ESTEBAN, R., VILADOMIU, J., et al. (1989). Hepatitis C virus antibodies among risk groups in Spain. Lancet 2, 294-297.
2. FRANCIS, D.P., HADLER, S.C., and PRENDERGAST, T.J. (1984). Occurrence of hepatitis A, B and non-A, non-B in the United States. Am. J. Med. 76, 69-74.
3. ALTER, H.J., PURCELL, R.N., SHIH, J., et al. (1989). Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321, 1494-1500.
4. DIBISCEGLIE, A.M., MARTIN, P., KASSIANIDES, C., et al. (1989). Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321, 1506-1510.
5. DAVIS, G.L., BALART, L.A., SCHIFF, E., et al. (1989). Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N. Engl. J. Med. 321, 1501-1506.
6. HADZIYANNIS, S.J. (1991). Use of interferon in the treatment of chronic hepatitis. J. Hepatol. 13, 521-526.
7. SCVARCZ, R., YUN, Z.B., SONNERBERG, A., et al. (1995). Combined treatment with Interferon alpha and ribavirin for chronic hepatitis C in patients with previous nonresponse or nonsustained response to interferon alone. J. Med. Virol. 46, 43-47.
8. KAKUMU, S., YOSHIOKA, R., WAKITA, T., et al. (1993). A pilot study of ribavirin and interferon β for the treatment of chronic hepatitis C. Gastroenterology 105, 507-512.
9. YAMAMUTU, A.M., CRESTEIL, D., and HOMBERG, J.C. (1993). Characterization of antiliver/kidney microsome antibody (anti LKM-1) from hepatitis C virus-positive and negative sera. Gastroenterology 104, 1762-1767.
10. FENTIMAN, I.S., BALKWILL, F.R., THOMAS, B.S., et al. (1985). An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur. J. Cancer Clin. Oncol. 24, 1299-1303.
11. THIERRY, V., and DESCOTES, J. (1994). Clinical toxicity of the interferons. Drug Safety 10, 115-150.
12. GISSLINGER, H., GILLY, B., WLOLSZCZUK, W., et al. (1992). Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon alpha. Clin. Exp. Immunol. 90, 363-367.
13. BURMAN, P., KARLSSON, F.A., OBERG, K., et al. (1985). Autoimmune thyroid disease in interferon-treated patients. Lancet 2, 100-101.
14. BERRIS, B., and FEINMAN, S.V. (1991). Thyroid dysfunction and liver injury following alpha interferon treatment of chronic viral hepatitis. Digest. Dis. Sci. 36, 1657-1660.
15. YOSHIOKA, K., KAKUMU, S., WAKITA, T., et al. (1992). Detection of hepatitis C virus by PCR and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology 16, 293-299.
16. MITA, E., HAYASHI, N., HAGIWARA, K., et al. (1993). Predicting interferon therapy efficacy from hepatitis C virus (HCV) genotype and RNA titer. Gastroenterology 104, A956.
17. PAVLOTSKY, J.M., ROUDOT-THURAVAL, F., SIMMONDS, P., et al. (1995). Extrahepatic immunogenic manifestations in chronic hepatitis C and hepatitis C virus genotypes. Ann. Int. Med. 122, 167-173.